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Dilated cardiomyopathy (DCM) is a heart-muscle disease characterized by ventricular dilatation and impaired heart
contraction and is heterogeneous both clinically and genetically. To date, 12 candidate disease loci have been
described for autosomal dominant DCM. We report the identification of a new locus on chromosome 6q12-16 in
a French family with 9 individuals affected by the pure form of autosomal dominant DCM. This locus was found
by using a genomewide search after exclusion of all reported disease loci and genes for DCM. The maximum
pairwise LOD score was 3.52 at recombination fraction 0.0 for markers D6S1644 and D6S1694. Haplotype
construction delineated a region of 16.4 cM between markers D6S1627 and D6S1716. This locus does not overlap
with two other disease loci that have been described in nonpure forms of DCM and have been mapped on 6q23-
24 and 6q23. The phospholamban, malic enzyme 1–soluble, and laminin-a4 genes were excluded as candidate
genes, using single-strand conformation polymorphism or linkage analysis.
Dilated cardiomyopathy (DCM) is a heart-muscle dis-
ease characterized by ventricular dilatation and impaired
systolic contraction leading to congestive heart failure
and sudden death. The disease appears to be familial in
20%–30% of patients (Keeling et al. 1995; Gru¨nig et
al. 1998) and is transmitted in an autosomal dominant
manner in 66% of patients (Mestroni et al. 1999b). Fa-
milial DCM exhibits both clinical variability and genetic
heterogeneity. Three disease loci have been linked to
autosomal dominant pure DCM: 1q32 (CMD1D [MIM
601494], Durand et al. 1995), 2q31 (CMD1G [MIM
604145], Siu et al. 1999), and 9q13-22 (CMD1B [MIM
600884], Krajinovic et al. 1995). Mutations in cardiac
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actin, desmin, and d-sarcoglycan genes mapped on
15q14, 2q35, and 5q33, respectively, have been identi-
fied in the disease by using a candidate-gene approach
(Olson et al. 1998; Li et al. 1999; Tsubata et al. 2000).
Loci for DCM associated with conduction-system dis-
ease have been mapped on chromosome 1q21.2, with
mutations reported in the LMNA (lamin A/C) gene
(CMD1A [MIM 115200]) (Kass et al. 1994; Fatkin et
al. 1999; Brodsky et al. 2000), 2q14-22 (CMD1H [MIM
604288]) (Jung et al. 1999), and 3p22-p25 (CMD1E
[MIM 601154]) (Olson and Keating 1996). Two disease
loci—on chromosomes 1q21.2, with mutations in the
LMNA gene (CMD1A, Brodsky et al. 2000), and 6q23
(CMD1F [MIM 602067], Messina et al. 1997)—have
also been described in DCM associated with skeletal-
muscle abnormalities. DCM associated with mitral valve
prolapse has been mapped on 10q21 (CMD1C [MIM
601493]) (Bowles et al. 1996), and a chromosomal locus
for DCM associated with sensorineural hearing loss has
been reported on 6q23-24 (CMD1J) (Scho¨nberger et al.
2000).
We report results of linkage analysis of a French family
in which affected individuals in three successive gener-
ations express the pure form of DCM. Family members
Figure 1 Pedigree showing haplotype reconstruction for chromosome 6q markers in a French family affected by autosomal dominant DCM. 0 p uncertain interpretation of genotypes even
after several independent experiments. Disease haplotype is boxed. Individuals with no clinical data are indicated by a cross. Blackened symbols indicate affected individuals, unblackened symbols
indicate asymptomatic individuals, and gray symbols indicate individuals with unknown DCM status.
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Table 1















(%) ECG Finding Comment
III5 H M/76 1.83 I !55 NA 155
III11 A F/66 1.58 I 51 40 43 VPB MR2/4
III12 U F/64 1.48 II NA NA 42 Isolated LV dysfunction
III13 U M/58 2.01 II 65 52 40 iLBB DCM but CAD
III16 H F/84 1.39 I 42 27 66 Left QRS axis MVP; MR3/4
IV7 U F/43 1.50 I 52 34 63 Isolated LV dilatation
IV12 U M/45 2.03 I 56 39 57 iRBB Isolated LV dilatation
IV14 A M/33 1.82 I 58 46 42
IV16 H F/39 1.85 I 54 36 61
IV18 A F/40 1.78 II 60 49 37 VPB
IV20 U F/35 2.09 II 50 35 57 VO2 p 19 ml/kg/min; CHF
IV22 H M/28 2.14 I 57 40 56
IV24 A M/60 1.95 I 68 58 30 iLBB, VPB
IV26 A F/55 1.61 II 73 60 36 VPB
IV28 A F/48 1.68 II 53 45 32
IV29 A F/55 1.55 I 54 40 50
V3 U M/19 1.96 I 52 40 48 LAH Isolated mild LV dysfunction
V7 H M/34 1.90 I 54 36 61
V10 A M/17 1.88 I 57 46 39
V11 H F/34 1.60 I 49 31 66
V12 U M/37 2.11 I 59 40 60 iLBB Isolated LV dilatation
V13 A F/29 1.75 II 78 58 49 iLBB
NOTE.— A p affected; BSA p body surface area; CAD p coronary artery disease; CHF p congestive heart failure; EF p
ejection fraction; Hp healthy carrier; iLBBp incomplete left bundle branch block; iRBBp incomplete right bundle branch block;
LAH p left atrium hypertrophy; LVp left ventricular; LVEDDp LV end diastolic diameter; LVESDp LV end systolic diameter;
MR p mitral regurgitation; MVP p mitral valve prolapse; NA p data not available; VPB p ventricular premature beats (1
triplet); U p unknown status. VO2 p maximal oxygen uptake during exercise.
a Age at genetic inquest and clinical evaluation.
Table 2
Pairwise LOD Scores for 11 Markers on
Chromosome 6
MARKERa
LOD SCORE AT v pb
.0 .01 .05 .1
D6S460 .10 .84 1.29 1.30
D6S445 2.56 2.52 2.34 2.10
D6S1627 1.39 .86 1.34 1.37
D6S1601 1.28 1.26 1.16 1.03
D6S1644 3.53 3.47 3.20 2.84
D6S1570 3.03 2.98 2.79 2.54
D6S462 1.83 1.80 1.65 1.47
D6S1694 3.52 3.46 3.23 2.93
D61720 3.30 3.25 3.01 2.70
D6S300 2.77 2.72 2.51 2.24
D6S1716 1.21 .61 1.13 1.20
a Markers are shown in order from cen-
tromere to telomere, according to Dib et al.
(1996).
b Maximum LOD scores are underlined.
received clinical evaluation, including electrocardiogram
(ECG) and echocardiography. Coronary angiography
was performed in the proband and in those relatives who
were suspected of having ischemic heart disease. The
diagnosis of DCM was based on major and minor cri-
teria established in a European collaboration (see details
in Mestroni et al. 1999a). A subject’s status was con-
sidered “unknown” if mild abnormalities or confound-
ing factors, such as coronary artery disease, were pre-
sent. A simplified pedigree of the family is presented in
figure 1. Clinical data of 22 subjects carrying the disease
haplotype are summarized in table 1. Of the nine sub-
jects who were diagnosed as phenotypically affected by
DCM, five had previously reported New York Heart
Association (NYHA) class III dyspnea, and three had
significant ventricular premature beats (with triplets).
Seven subjects carrying the common haplotype were
considered to have unknown status in the linkage anal-
ysis, because of the presence of mild cardiac abnormal-
ities that included isolated left ventricular (LV) diameter
enlargement (individuals IV7, IV12, and V12), isolated
low ejection fraction (individuals III12 and V3), signif-
icant coronary artery disease that could interfere with
the diagnosis of DCM (individual III13), and congestive
heart failure (individual IV20). No subject had a con-
duction defect or skeletal muscle abnormalities at clinical
examination.
Blood samples from 51 persons were obtained, and
genomic DNA was extracted using standard procedures,
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Figure 2 Ideogram of chromosome 6 with approximate location of DCM loci and flanking markers
in collaboration with the Ge´ne´thon Bank. Informed con-
sent was obtained from all participants, in accordance
with requirements of the Pitie´-Salpeˆtrie`re hospital ethics
committee. To map the disease gene, we performed a
genomewide scan with 342 fluorescent microsatellite
markers selected from the Ge´ne´thon human linkage map
(Dib et al. 1996), which covers the entire human genome
with a resolution of ∼10 cM. Markers were amplified
by PCR (Dib et al. 1996) and were separated on an
automatic ABI 377 DNA sequencer before analysis with
the GENESCAN version 2.2 and GENOTYPER version
2.0 software (Applied Biosystems).
Pairwise calculations were performed with MLINK
version 5.2, under an autosomal dominant model. The
allele frequencies of the microsatellite markers were set
as equal (1/n), and frequencies for the disease and nor-
mal allele were set at .0003 and .9997, respectively (Kra-
jinovic et al. 1995). No sex difference was considered.
Penetrance of the disease, calculated according to the
method of Johnson et al. (1996), was estimated at 60%
(Johnson et al. 1996; Mangin et al. 1999). After exclu-
sion of all known loci, a scan of the entire autosomal
genome was performed, allowing us to exclude ∼90%
of the genome. Positive pairwise LOD scores (Z) were
obtained for chromosomes 2, 10, and 13, but the loci
were excluded by additional marker genotyping and
haplotype reconstruction. The cardiac actin and desmin
loci, which mapped on 15q14 and 2q35, respectively,
were excluded by both genotyping and SSCP analysis of
coding regions (cardiac active gene [J00070, J00071,
J00072, and J00073] and desmin gene [M58168]) (Tes-
son et al. 2000). The lamin A/C gene was also excluded
by genotyping and SSCP analysis of the entire coding
sequence (L12399, L12400, and L12401). Haplotype
reconstruction showed that all affected subjects, as well
as all individuals with unknown status, shared a com-
mon haplotype on chromosome 6, between markers
D6S1627 and D6S1716 (fig. 1). The candidate interval
corresponds to a 16.4-cM region localized on chromo-
some 6q12-16. Using the parameters described earlier in
this paragraph, we obtained maximum pairwise LOD
scores of 3.53 and 3.52 with markers D6S1644 and
D6S1694, respectively, at recombination fraction (v)p
0.0 (table 2). The pairwise LOD scores for both markers
remained significant, at , when penetrance wasvp 0.0
estimated at 75% and at 90% (the pairwise LOD score
was 3.68 at 75% penetrance and was 3.48 at 90% pen-
etrance for marker D6S1644, and the respective LOD
scores were 3.35 and 2.77 for marker D6S1694). Results
obtained using the published allele frequencies of the
CEPH families (Dib et al. 1996) showed a pairwise LOD
score of 3.98 and 3.41 for markers D6S1644 and
D6S1694, respectively. When all individuals with un-
known status were considered as affected, the pairwise
LOD score for both markers reached 6.5 at ,vp 0.0
using an estimated penetrance of 60% and equal allele
frequencies.
The presence of five clinically unaffected adults (sub-
jects III5, III16, IV22, V7, and V11), who were 28–84
years old and who carried the entire disease haplotype,
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points out the incomplete penetrance of the disease in
this family. Subject IV16 carried the partial disease hap-
lotype yet was asymptomatic and had strictly normal
results on cardiovascular examination, ECG, and echo-
cardiography (table 1). These observations are in agree-
ment with those reported by Mangin et al. (1999), which
showed an incomplete age-related penetrance in 13 un-
related families. The present family exhibits no signifi-
cant sex-related penetrance. Individual III16 is known
to have transmitted the disease haplotype, because one
of his children (IV24) was clinically affected. Further-
more, seven individuals (III12, III13, IV7, IV12, IV20,
V3, and V12) classified as having unknown status were
also carriers of the disease haplotype, suggesting that the
minor abnormalities were a mild form of the disease.
The incomplete penetrance of the disease within this
family and the heterogeneous expression suggest the in-
volvement of other factors, such as modifying genes and/
or environmental factors, in the phenotypic expression.
Similar results have been observed in familial hyper-
trophic cardiomyopathy, which is also characterized by
highly incomplete penetrance (Charron et al. 1997;
Moolman et al. 2000).
According to the Ge´ne´thon linkage map, this third
locus on chromosome 6q is localized in a centromeric
region 22 cM away from the disease locus described by
Messina et al. (1997) and 29 cM away from the locus
reported by Scho¨nberger et al. (2000). Linkage analysis
using markers D6S262 and D6S457, both localized in
the telomeric boundary of the intervals described by
these authors, allowed us to exclude the present locus
(Z at ) from these distal intervals (fig. 2).v ! 2
The disease interval on chromosome 6q12-16 re-
ported here contains known genes encoding collagen IX-
a-1 polypeptide (COL9A1 [MIM 120210]), myosin VI
(MYO6 [MIM 600970]), vascular endothelial growth
factor (VEGF [MIM 192240]), malic enzyme cytoplas-
mic (ME1 [MIM 154250]) and several other genes en-
coding anonymously expressed sequence tags. In addi-
tion, the genes encoding cardiac phospholamban (PLN
[MIM 600133]) and laminin-a4 (LAMA4 [MIM
600133]), located near the disease interval, could also
be considered as candidate genes. We therefore screened
for mutation the entire coding sequence and promotor
region of PLN (Z99496) and ME1 (NM002395) genes
by PCR and SSCP. We did not detect any gene defects
that could cause DCM. LAMA4 gene has been excluded
by linkage analysis using the microsatellite marker
D6S416 in intron 29 (X91171) (Dib et al. 1996). The
screening of the remaining candidate genes within the
6q12-16 region is in progress in our laboratory.
Acknowledgments
These studies would not have been possible without the
invaluable assistance of patients and family members. We also
thank Jean Weissenbach (Genoscope-Evry), Arnaud Lema-
inque and Sylvana Pavek (CNG-Evry) for their contribution
to genotyping, and Safa Saker and the personnel of Ge´ne´thon’s
Bank for DNA extraction and cell lines. We thank Pascale
Sebillon for her critical review of the manuscript. This work
was made possible by generous grants from the Association
Franc¸aise contre les Myopathies, the Fe´de´ration Franc¸aise de
Cardiologie, INSERM, and Jeanne Laroche (private grant).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
GenBank: http://www.ncbi.nlm.nih.gov/Genbank/ (for cardiac
actin gene [accession numbers J00070, J00071, J00072, and
J00073], desmin gene [accession number M58168], LMNA
gene [accession numbers L12399, L12400, and L12401],
ME1 gene [accession number NM002395], PLN gene [ac-
cession number Z99496], and LAMA4 gene [accession num-
ber X91171])
Ge´ne´thon, http://www.genethon.fr (microsatellite markers and
chromosome 6 linkage map)
Online Mendelian Inheritance in Man (OMIM): http://www
.ncbi.nlm.nih.gov/Omim/ (for CMD1A [MIM 115200],
CMD1B [MIM 600884], CMD1C [MIM 601493],
CMD1D [MIM 601494], CMD1E [MIM 601154],CMD1F
[MIM 602067], CMD1G [MIM 604145], CMD1H [MIM
604288], COL9A1 [MIM 120210], MYO6 [MIM 600970],
VEGF [MIM 192240], PLN [MIM 600133], ME1 [MIM
154250], and LAMA4 [MIM 600133])
References
Bowles KR, Gajarski R, Porter P, Goytia V, Bachinski L, Rob-
erts R, Pignatelli R, Towbin JA (1996) Gene mapping of
familial autosomal dominant dilated cardiomyopathy to
chromosome 10q21-23. J Clin Invest 98:1355–1360
Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mes-
troni L (2000) Lamin A/C gene mutation associated with
dilated cardiomyopathy with variable skeletal muscle in-
volvement. Circulation 101:473–476
Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Ri-
chard P, Bonne G, Guicheney P, Hainque B, Bouhour JB,
Mallet A, Feingold J, Schwartz K, Komajda M (1997) Pen-
etrance of familial hypertrophic cardiomyopathy. Genet
Couns 8:107–114
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A,
Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gya-
pay G, Morissette J, Weissenbach J (1996) A comprehensive
genetic map of the human genome based on 5,264 micro-
satellites. Nature 380:152–154
Durand JB, Bachinski LL, Bieling LC, Czernuszewicz GZ, Ab-
chee AB, Yu QT, Tapscott T, Hill R, Ifegwu J, Marian AJ,
Brugada R, Daiger S, Gregoritch JM, Anderson JL, Qui-
nones M, Towbin JA, Roberts R (1995) Localization of a
gene responsible for familial dilated cardiomyopathy to
chromosome 1q32. Circulation 92:3387–3389
Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Fren-
neaux M, Atherton J, Vidaillet HJ Jr, Spudich S, De Girolami
U, Seidman JG, Seidman CE, Muntoni F, Muehle G, Johnson
246 Am. J. Hum. Genet. 68:241–246, 2001
W, McDonough B (1999) Missense mutations in the rod
domain of the lamin A/C gene as causes of dilated cardio-
myopathy and conduction-system disease. N Engl J Med
341:1715–1724
Gru¨nig E, Tasman JA, Ku¨cherer H, Franz W, Ku¨bler W, Katus
HA (1998) Frequency and phenotypes of familial dilated
cardiomyopathy. J Am Coll Cardiol 31:186–194
Johnson WG, Kugler SL, Stenroos ES, Meulener MC, Rang-
walla I, Johnson TW, Mandelbaum DE (1996) Pedigree
analysis in families with febrile seizures. Am J Med Genet
61:345–352
Jung M, Poepping I, Perrot A, Ellmer AE, Wienker TF, Dietz
R, Reis A, Osterziel KJ (1999) Investigation of a family with
autosomal dominant dilated cardiomyopathy defines a novel
locus on chromosome 2q14-q22. Am J Hum Genet 65:
1068–1077
Kass S, MacRae C, Graber HL, Sparks EA, McNamara D,
Boudoulas H, Basson CT, Baker PB 3d, Cody RJ, Fishman
MC, Cox N, Kong A, Wooley CF, Seidman JG, Seidman CE
(1994) A gene defect that causes conduction system disease
and dilated cardiomyopathy maps to chromosome 1p1-1q1.
Nat Genet 7:546–551
Keeling PJ, Gang Y, Smith G, Seo H, Bent SE, Murday V,
Caforio AL, McKenna WJ (1995) Familial dilated cardio-
myopathy in the United Kingdom. Br Heart J 73:417–421
Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM,
Milasin J, Falaschi A, Giacca M (1995) Linkage of familial
dilated cardiomyopathy to chromosome 9. Heart Muscle
Disease Study Group. Am J Hum Genet 57:846–852
Li D, Tapscoft T, Gonzalez O, Burch PE, Quinones MA,
Zoghbi WA, Hill R, Bachinski LL, Mann DL, Roberts R,
(1999) Desmin mutation responsible for idiopathic dilated
cardiomyopathy. Circulation 100:461–464
Mangin L, Charron P, Tesson F, Mallet A, Dubourg O, Desnos
M, Benaı¨che A, Gayet C, Gibelin P, Davy JM, Bonnet J, Sidi
D, Schwartz K, Komajda M (1999) Familial dilated car-
diomyopathy: clinical features in French families. Eur J
Heart Failure 1:353–361
Messina DN, Speer MC, Pericak-Vance MA, McNally EM
(1997) Linkage of familial dilated cardiomyopathy with con-
duction defect and muscular dystrophy to chromosome
6q23. Am J Hum Genet 61:909–917
Mestroni L, Maı¨sch B, McKenna WJ, Schwartz K, Charron P,
Rocco C, Tesson F, Richter A, Wilke A, Komajda M (1999a)
Guidelines for the study of familial dilated cardiomyopa-
thies. Collaborative Research Group of the European Hu-
man and Capital Mobility on Familial Dilated Cardiomy-
opathy. Eur Heart J 20:93–102
Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A,
Miocic S, Vatta M, Pinamonti B, Muntoni F, Caforio AL,
McKenna WJ, Falaschi A, Giacca M, Camerini F (1999b)
Familial dilated cardiomyopathy: evidence for genetic and
phenotypic heterogeneity. J Am Coll Cardiol 34:181–190
Moolman JA, Reith S, Uhl K, Bailey S, Gautel M, Jeschke B,
Fischer C, Ochs J, McKenna WJ, Klues H, Vosberg HP
(2000) A newly created splice donor site in exon 25 of the
MyBP-C gene is responsible for inherited hypertrophic car-
diomyopathy with incomplete disease penetrance. Circula-
tion 101:1396–1402
Olson TM, Keating MT (1996) Mapping a cardiomyopathy
locus to chromosome 3p22-p25. J Clin Invest 97:528–532
Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT
(1998) Actin mutations in dilated cardiomyopathy, a heri-
table form of heart failure. Science 280:750–752
Scho¨nberger J, Levy H, Gru¨nig E, Sangwatanaroj S, Fatkin D,
MacRae C, Sta¨cker H, Halpin C, Eavey R, Philbin EF, Katus
H, Seidman JG, Seidman CE (2000) Dilated cardiomyopathy
and sensorineural hearing loss: a heritable syndrome that
maps to 6q23-24. Circulation 101:1812–1818
Siu BL, Niimura H, Osborne JA, Fatkin D, MacRae C, Sol-
omon S, Benson DW, Seidman JG, Seidman CE (1999) Fa-
milial dilated cardiomyopathy locus maps to chromosome
2q31. Circulation 99:1022–1026
Tesson F, Sylvius N, Pilotto A, Duboscq Bidot L, Peuchmaurd
M, Bouchier C, Be´naı¨che A, Mangin L, Charron P, Gavazzi
A, Tavazzi L, Arbustini E, Komajda M (2000) Epidemiology
of desmin and cardiac actin gene mutations in a European
population of dilated cardiomyopathy. Eur Heart J 21:
1872–1876
Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen
L, Bowles NE, Towbin JA (2000) Mutations in the human
d-sarcoglycan gene in familial and sporadic dilated cardio-
myopathy. J Clin Invest 106:655–662
